RayKnowChina Research Map
Shortlist

Blood disorders

Lymphoma in Hefei

合肥 淋巴瘤

All diseases in Hefei

4 hospitals in Hefei

Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Hefei may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 16 papers led
    No open trial led
  2. 13 papers led
  3. 9 papers led
    No open trial led
  4. 0 papers led
    No open trial led

Lymphoma in every city Hefei on the disease page, with the national map

25

open trials on lymphoma with a hospital in Hefei

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Hefei as lead sponsor or study site. 3 of them are led by a hospital in Hefei. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    Anti CD19 Gene Therapy for B-cell Lymphoma
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07211048

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  2. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  3. Recruiting
    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06717347

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen

  4. Recruiting
    Newly-diagnosed Pediatric T-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06855810

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan

  5. Recruiting
    Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06961669

    Age 3 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  6. Recruiting
    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07059650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou

  7. Recruiting
    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07082686

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  8. Recruiting
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Early phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07093411

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad Hospital; 3 listed hospitals as study sitesBeijing, Hefei, Xi'an, Xuzhou

  9. Recruiting
    A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07154264

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou

  10. Recruiting
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07188610

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  11. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  12. Recruiting
    The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2024-03
    Posted
    Registry
    NCT06307600

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan

  13. Recruiting
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06363994

    Age 60 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  14. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  15. Recruiting
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06395870

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteHefei, Tianjin

  16. Recruiting
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT07234162

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  17. Recruiting
    Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
    Phase
    Phase 1/Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT05698147

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou

  18. Recruiting
    A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06136559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou

  19. Recruiting
    A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Phase
    Phase 3
    Started
    2022-07
    Posted
    Registry
    NCT05254743

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan

  20. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  21. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  22. Recruiting
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
    Phase
    Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04728893

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  23. Recruiting
    Evaluate the Safety and Clinical Activity of HH2853
    Phase
    Phase 1/Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04390737

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou

  24. Not yet recruiting
    A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07784101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  25. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Hefei

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Hefei, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital, Anhui University of Chinese Medicine安徽中医药大学神经病学研究所附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Anhui Chest Hospital安徽省胸科医院nonenonenonenone16nonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Anhui Chest Hospitalnonenonenonenone11 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Anhui Provincial Cancer Hospital安徽省肿瘤医院none0none0100nonenonenonenone0nonenonenone0nonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone
Anhui Provincial Children's Hospital安徽省儿童医院nonenonenonenonenonenonenonenone11nonenonenone8nonenone1nonenonenonenone0nonenonenonenonenonenonenonenone2none3nonenonenonenonenonenonenone00nonenonenonenonenonenonenonenonenonenonenone1nonenone0nonenonenonenone
First Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院3231018482256732none0none1301110none1none9nonenonenone21nonenone4none1none228none72none5nonenonenonenonenone0nonenone11none0none32012none01nonenonenone
First Affiliated Hospital of Anhui University of Chinese Medicine安徽中医药大学第一附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone52nonenonenonenonenonenonenonenonenone2nonenonenonenonenonenone5nonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)2176 open914 open22682 open205244nonenonenone344none22 open12 open21 opennone133 opennone2none100none156none186none0nonenone211none2nonenone011nonenonenone0001nonenonenonenonenonenonenone
Fourth Affiliated Hospital of Anhui Medical University安徽医科大学第四附属医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hefei Binhu Hospital合肥市第一人民医院滨湖院区nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hefei BOE Hospital合肥京东方医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Hefei Maternal and Child Health Hospital合肥市妇幼保健院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Internet Hospital平安(合肥)互联网医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Police Forces Anhui Provincial Corps Hospital武警安徽省总队医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院none12721283381 open17none1none612174none116none4none1none2nonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenone0nonenonenone1nonenonenonenonenonenonenonenonenonenone
South District Binhu Hospital合肥市第一人民医院南区nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Anhui Medical University合肥市第一人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Hefei.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lymphoma.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Hefei on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data